This is because obesity would result in a systemic and chronic inflammatory environment by increasing the secretion of pro-inflammatory adipokines, e.g., visfatin, leptin, resistin, etc., and this condition would benefit the CRC development and attenuate the drug efficacy of patients [9,10,11]. The gene discussed is NAMPT; the disease is obesity disorder.